Skip to the stories
Saturday, 31 October 2026
Saved

Next edition

2:26

Headlines

Funding Rounds

Dren Bio secures 350 million dollars for lead cancer drug launch

Clinical stage antibody developer Dren Bio has raised 350 million dollars in private funding to advance its lead therapy dibotatug toward regulatory submission and commercial launch.

FTMQ Startups, written by our newsroom0 views

Share

Clinical stage biopharmaceutical company Dren Bio has closed a 350 million dollar private financing round, Wowtale and Pulse 2.0 reported. The investment was co-led by Juvia Group and Lightspeed Venture Partners. Pulse 2.0 described the round as oversubscribed. [1][2]

The financing included new investments from Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Management, and OrbiMed, according to Wowtale and Pulse 2.0. Existing investors 8VC, SR One, and Taiho Ventures also participated in the transaction. Wowtale noted that Dren Bio did not state a series letter or disclose its valuation for the round. [1][2]

According to Wowtale and Pulse 2.0, Dren Bio will use the fresh capital to fund the late stage development, regulatory submission, and commercial launch of its lead antibody therapy dibotatug, also known as DR-01. The therapeutic candidate is designed as an antibody that depletes disease driving immune cells. Pulse 2.0 added that the proceeds will also support the expansion of Dren Bio's broader oncology and autoimmune pipeline. [1][2]

The capital injection comes as Dren Bio prepares its blood cancer drug program for regulatory submission, with Endpoints News and Dealroom reporting that the company is targeting a potential market launch in 2027. [9][10]

Share

In short

  • Dren Bio raised 350 million dollars in a private financing round co-led by Juvia Group and Lightspeed Venture Partners.
  • New backers included Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Management, and OrbiMed.
  • The round was oversubscribed and Dren Bio did not disclose a valuation.
  • Funds will support late stage development, regulatory filing, and a planned launch of lead therapy dibotatug.

Sources

Every paragraph above points to the numbered items it rests on. Read the originals here.

  1. [1]Dren Bio Raises $350M to Bring a Blood Cancer Antibody to Market, Led by Juvia Group and LightspeedWowtale, 3h ago (the report this story comes from)
  2. [2]Dren Bio Raises $350 Million To Advance Dibotatug And Broader Therapeutics PipelinePulse 2.0, 12h ago
  3. [3]Midstream Health Raises $20 Million Series A Led By ValtruisPulse 2.0, 10h ago
  4. [4]Wabi Raises $55 Million At $1.25 Billion Valuation Led By IVPPulse 2.0, 10h ago
  5. [5]Serval Raises $150 Million Series C At $3 Billion Valuation Led By SequoiaPulse 2.0, 10h ago
  6. [6]Lette Raises $6.5 Million Seed Funding Led By Peak To Scale AI-Powered Rental OperationsPulse 2.0, 15h ago
  7. [7]Dren Bio pockets $350m for rare blood cancer programmepharmaphorum, 1d ago
  8. [8]Dren Bio raises $350 million to advance blood cancer drugThe Pharma Letter, 9h ago
  9. [9]Exclusive: Dren Bio nabs $350M for potential 2027 launch of blood cancer drugEndpoints News, 1d ago
  10. [10]Dren Bio raises $350M to push its own blood cancer drug toward a 2027 launchDealroom, 1d ago
  11. [11]Dren Bio lands $350M to push rare blood cancer therapy toward marketBioSpace, 1d ago

Background

  1. [12]Dren McDonald on Wikipedia
  2. [13]Antibody microarray on Wikipedia
  3. [14]List of Fairy Tail: 100 Years Quest episodes on Wikipedia

Our newsroom writes these reports with the help of software, from the 14 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.

Related from FTMQ Startups

Earlier reports of ours on the same people and subjects.

More in Funding Rounds

Get the day in one email

Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments

Loading

Join the conversation

Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.

Already on the list? Enter the same address and we will send a sign-in link.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.